Immunovant price target lowered to $38 from $45 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacific Biosciences (PACB – Research ...
STAT22h
NIH plans to slash support for indirect research costs, sending shockwaves through science
The National Institutes of Health, the nation’s premier funder of biomedical research, announced Friday night that it will immediately slash support for “indirect costs” paid to universities ...
Greenhouse Management22h
AMVAC, DPH Biologicals sign regional distribution agreement
AMVAC will also distribute future product offerings, utilizing DPH Bio’s TerraTrove technology platform for biofertilizers ...
Common Sense Media20h
Movies with Inspiring Black Girls and Women
Musical take on classic fairy tale is an inclusion landmark.